Tirzepatide exerts its therapeutic effects through dual agonism of two key incretin receptors: the GIPR and the GLP-1R
Stopping GLP-1 Therapy: New Data Highlight the Challenge of Weight Regain Mar 27, 2026 Articles, Diabetes, GLP- 1 Agonist Therapy Center, GLP-1 Agonist Therapy Center, Obesity 1,529 views Have you ever wondered why weight seems to come back so quickly after stopping a medication that once worked so well
For a detailed comparison including when each type is appropriate, see Bac Water vs Sterile Water vs Saline: What to Use
Convenient daily sachet format
However, when this balance collapses, immune signals are converted into pathological drivers that continuously amplify fibroblast activation and tissue stiffening (Mescher 2017)
They work by regulating appetite, slowing gastric emptying, reducing cravings, and improving insulin sensitivity